×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Brielle Urciuoli
A new treatment has been approved to treat two rare forms of non-Hodgkin lymphoma. 
DEBU TRIPATHY, M.D.
With an incidence rate of about three cases per million people a year in the United States, Waldenstrom macroglobulinemia is a rare malignancy, and, therefore, has no widely used screening tools. Diagnosing the disease early and, most important, accurately is the art of medicine that remains to be perfected.
Shira Zwebner
Sometimes, you're ill prepared for a scan that might change the course of your life.
ERIK NESS
This incurable rare cancer of the lymphatic system has seen improvements, but what is the best strategy for treating patients with the disease?
Kristie L. Kahl
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
Peter Borchmann, M.D.
CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.
Shira Zwebner
How do you stay positive when surrounded by death and dying?
Jason M. Broderick
The FDA has granted a priority review to a supplemental new drug application (sNDA) Imbruvica (ibrutinib) for use in combination with Rituxan (rituximab) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia.
Katie Kosko
Treatment with chimeric antigen receptor (CAR)-T cell therapy showed encouraging rates of durable responses among adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the pivotal JULIET trial.
 
Shira Zwebner
Why the proverb, "you should never judge a man until you've walked a mile in his shoes" is true for both cancer patients and survivors.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable